• New financing from lead o2h Ventures and Syndicate Room, follows funding from Jonathan Milner and Start Codon, announced in July 2020
  • Spirea’s novel antibody drug conjugate platform technology has been successfully validated following in vitro and in vivo proof-of-concept studies

Cambridge, UK, 07 December 2020: Spirea Limited (Spirea), a spin-out from the University of Cambridge, which was founded to deliver the next generation of antibody drug conjugate (ADC) cancer therapeutics, has today announced that it has secured financing from lead o2h Ventures and Syndicate Room. The investment will be used to enable Spirea’s ADC therapeutic programmes ahead of a significant Seed financing anticipated in 2021. The Company also announces the successful in vivo validation of the platform in proof-of-concept studies using a cancer xenograft model.

ADC drugs combine the cell killing activity of a cytotoxic drug payload with the targeting ability of an antibody. However, toxic side-effects, limited flexibility, and the resulting limitations in the range of cancers that can be treated have restricted the field and caused many clinical programmes to stall. Spirea’s novel technology overcomes these issues by offering high drug-to-antibody ratio (DAR) and a design flexibility which enables the development of differentiated ADCs with improved efficacy and safety. Because the technology allows more drug to be loaded onto the targeting antibody whilst maintaining drug stability, payloads can also be customised to the target, enabling flexibility in payload potencies, creative drug combinations and novel modes of action to serve a wider patient group.

Dr Myriam Ouberai, CEO of Spirea, commented: “We have now demonstrated that our ADC technology performs extremely well in vivo. The funding and support from o2h Ventures and Syndicate Room serve as an endorsement of our approach and will allow us to start building a pipeline of exciting therapeutic products based on our validated technology.”

Sunil Shah, CEO at o2h Ventures, said: “Spirea’s potentially transformative approach to addressing the common obstacles faced in ADC development has the potential to disrupt this field entirely, placing the Company in a unique position to address a very significant market opportunity. This is an exciting time for Spirea and we are pleased to be supporting them.”

Spirea has previously received investment from Jonathan Milner, Start Codon, Innovate UK, IP Group and Cambridge Enterprise and is supported by a number of successful, high-profile board members from the life sciences including Jane Dancer (former Chief Business Officer at F-star), Gaynor Fryers (former Vice-President of Business Development at AstraZeneca) and Christine Martin (Deputy Head of Seed Funds at Cambridge Enterprise). Spirea benefits from being part of the healthcare business accelerator Start Codon and the Cambridge Judge Business School Entrepreneurship Centre’s Accelerator, Accelerate Cambridge.

For further information about Spirea, please visit: www.spirea.co.uk